Experteam was founded in 1996 by molecular biologists Angelo De Bortoli & Federica Schiavon in Venice, Italy. Starting with a series of innovative molecular biology kits for detection of virus, protozoa, bacteria and for detection of carcinomas and genetic disorders.
The company now has an extensive range of reliable and robust molecular kits. Currently Experteam consists of a R&D and production department and a sales division. Experteam is committed to provide the market with customized solutions in the field of molecular diagnostics.
Besides infertility, Experteam concentrates on oncology, genetic diseases, human virology and microbiology and environmental and food orientated microbiology and virology. The base of a wide range of products is the molecular detection using the Polymerase Chain Reaction (PCR) with either real- time PCR or gel or capillary electrophoresis. In addition to these techniques Experteam offer quantitative fluorescence PCR (QF-PCR) kits.
EXPCELI - SVILUPPO DI UN PROGRAMMA INFORMATICO INTEGRATO AL TERMOCICLATORE REAL TIME PCR PER LA REFERTAZIONE DELLA PREDISPOSIZIONE GENETICA ALLA CELIACHIA
SO.SI.A.Q. "SOSTENIBILE, SICURO, DI ALTA QUALITÀ: UN PROGETTO INTEGRATO DI RICERCA INDUSTRIALE PER L'INNOVAZIONE DELLA FILIERA MOLLUSCHICOLA DEL VENETO"
MESSA A PUNTO DI UN KIT DIAGNOSTICO MOLECOLARE UNIVERSALE PER LA RILEVAZIONE DI PATOGENI IN ALIMENTI E ACQUE
L'AGRICOLTURA DEL FUTURO E GLI ALIMENTI FUNZIONALI: UNA SFIDA PER LA RICERCA E IL RILANCIO DEL TERRITORIO VENETO (F.A.&A.F.)
Experteam offers kits for the detection of DM1 and DM2 expanded alleles using “long range PCR”, “TP-PCR”, and Southern blotting as suggested by the guidelines “EMQN Best Practice Guidelines and Recommendations on Myotonic Dystrophy types 1 and 2”.
Huntington’s disease (HD) is a dominantly transmitted neurodegenerative disorder with wide variation in onset age but with an average age at onset of 40 years. HD is caused by the expansion of an unstable polymorphic tri-nucleotide (CAG)n repeat in exon 1 of the HTT gene (4p16.3). Repeats of 36 or larger are associated with disease expression, whereas repeats of 26 and smaller are normal. Intermediate numbers of repeats, could be associated with reduced penetrance whereby some develop HD and others do not.
PAI 1 coagulation Kit-RQ
Plasminogen activator inhibitor type 1 (PAI-1) is an important component of the coagulation system that down-regulates fibrinolysis in the circulation. Elevated circulating levels of PAI-1, have been related to the development of myocardial infarction.
There is evidence that a single nucleotide insertion/deletion (4G/5G) polymorphism in the promoter region of the PAI-1 gene is associated with circulating PAI-1 levels.